Piergiorgio Cojutti

List of Publications by Year
in descending order

55 papers	1,498 citations	304743 22 h-index	330143 37 g-index

55 all docs	55 docs citations	55 times ranked	1352 citing authors

#	Article	IF	Citations
1	Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 2034-2042.	3.0	208
2	Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis. Antimicrobial Agents and Chemotherapy, 2010, 54, 4605-4610.	3.2	172
3	Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach. Antimicrobial Agents and Chemotherapy, 2012, 56, 6343-6348.	3.2	76
4	Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. International Journal of Antimicrobial Agents, 2017, 49, 255-258.	2.5	65
5	A 10â€Year Experience of Therapeutic Drug Monitoring (<scp>TDM</scp>) of Linezolid in a Hospitalâ€wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting <scp>TDM</scp> in the Majority of Patients?. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 303-308.	2.5	64
6	Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	63
7	TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient. Annals of Pharmacotherapy, 2011, 45, 1022-1022.	1.9	52
8	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	44
9	Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Critical Care, 2022, 26, .	5.8	41
10	Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3588-3595.	3.0	35
11	Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(<scp>CYP</scp>) Inhibitors and/or with <scp>CYP</scp> Inhibitors plus <scp>CYP</scp> Inducers. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 474-479.	2.5	34
12	Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMIÂâ‰¥40Âkg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring. Clinical Pharmacokinetics, 2014, 53, 753-762.	3.5	33
13	Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 2015, 70, 198-206.	3.0	33
14	Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. Clinical Pharmacokinetics, 2015, 54, 933-941.	3.5	31
15	Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	28
16	Pharmacokinetic Interaction Between Everolimus and Antifungal Triazoles in a Liver Transplant Patient. Annals of Pharmacotherapy, 2008, 42, 1711-1716.	1.9	27
17	Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures. Therapeutic Drug Monitoring, 2014, 36, 674-676.	2.0	26
18	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clinical Pharmacokinetics, 2018, 57, 989-1000.	3.5	26

#	Article	IF	Citations
19	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 2017, 72, 2342-2350.	3.0	26
20	Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clinical Pharmacokinetics, 2020, 59, 1251-1260.	3.5	25
21	Successful Long-Term Treatment of Cerebral Nocardiosis with Unexpectedly Low Doses of Linezolid in an Immunocompromised Patient Receiving Complex Polytherapy. Antimicrobial Agents and Chemotherapy, 2012, 56, 3438-3440.	3.2	24
22	Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderl. Pharmacoepidemiology and Drug Safety, 2016, 25, 1070-1078.	1.9	24
23	Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3029-3037.	3.0	24
24	Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: Dose Intensification Coupled with Avoidance of Proton Pump Inhibitors Is Beneficial in Shortening Time to Effective Concentrations. Antimicrobial Agents and Chemotherapy, 2013, 57, 6081-6084.	3.2	23
25	Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. Journal of Antimicrobial Chemotherapy, 2014, 69, 2585-2586.	3.0	23
26	Coâ€administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayedâ€released tablets in adult patients with haematological malignancies. British Journal of Clinical Pharmacology, 2018, 84, 2544-2550.	2.4	20
27	Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection, 2014, 42, 207-210.	4.7	18
28	A 1Âyear retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?. British Journal of Clinical Pharmacology, 2016, 81, 341-348.	2.4	18
29	Does Critical Illness Change Levofloxacin Pharmacokinetics?. Antimicrobial Agents and Chemotherapy, 2016, 60, 1459-1463.	3.2	17
30	Pharmacokinetics and Pharmacodynamics of Continuous-Infusion Meropenem in Pediatric Hematopoietic Stem Cell Transplant Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 5535-5541.	3.2	16
31	Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Medicine, 2015, 41, 366-368.	8.2	13
32	Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?. Journal of Antimicrobial Chemotherapy, 2016, 71, 1323-1329.	3.0	13
33	Gentamicin once-daily in enterococcal endocarditis. International Journal of Cardiology, 2013, 168, 5033-5034.	1.7	12
34	Limited sampling strategies for determining the area under the plasma concentrationâ€“time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. International Journal of Antimicrobial Agents, 2017, 50, 23-28.	2.5	12
35	Treatment of Candida infections with fluconazole in adult liver transplant recipients: Is TDMâ€guided dosing adaptation helpful?. Transplant Infectious Disease, 2019, 21, e13113.	1.7	12
36	Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2021, 58, 106408.	2.5	12

#	Article	IF	Citations
37	Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Frontiers in Pharmacology, 2021, 12, 781892.	3.5	12
38	Validation of Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure During the First Year After Heart Transplantation. Transplantation Proceedings, 2009, 41, 4277-4284.	0.6	11
39	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2019, 74, 1648-1655.	3.0	11
40	Linezolid underexposure in a patient co-treated with venlafaxine. European Journal of Clinical Pharmacology, 2015, 71, 1285-1286.	1.9	10
41	Successful and safe longâ€term treatment of cerebral aspergillosis with highâ€dose voriconazole guided by therapeutic drug monitoring. British Journal of Clinical Pharmacology, 2019, 85, 266-269.	2.4	8
42	Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. International Journal of Antimicrobial Agents, 2014, 44, 570-571.	2.5	7
43	Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study. Therapeutic Drug Monitoring, 2020, 42, 349-352.	2.0	7
44	Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. Transplant Infectious Disease, 2015, 17, 926-928.	1.7	6
45	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.. European Journal of Clinical Pharmacology, 2018, 74, 1449-1459.	1.9	6
46	Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa. Pharmaceutics, 2020, 12, 785.	4.5	6
47	Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 432-437.	2.5	5
48	A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy. Diagnostic Microbiology and Infectious Disease, 2015, 81, 53-56.	1.8	5
49	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. European Journal of Clinical Pharmacology, 2018, 74, 1091-1092.	1.9	5
50	Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. Journal of Global Antimicrobial Resistance, 2018, 14, 238-241.	2.2	4
51	Continuous Infusion May Improve the Efficacy of Vancomycin in Treatment of Experimental Endocarditis Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2011, 55, 4496-4497.	3.2	2
52	Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Clinical Pharmacokinetics, 2022, 61, 505-513.	3.5	2
53	Reply to Baklouti et al., â€œWhy Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?â€• Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0190821.	3.2	1
54	Authorsâ€™ Reply to Cattaneo et al.: â€œComment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6â€• Clinical Pharmacokinetics, 2021, 60, 833-834.	3.5	0

#	Article	IF	Citations
55	Drugs and Blood Cells. , 2015, , 111-147.		0